A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Amer M. Zeidan(Yale Cancer Center), Eunice S. Wang(Roswell Park Comprehensive Cancer Center)

Clinical Cancer Research

September 30, 2020

10.1158/1078-0432.ccr-20-2586

Cited by 89

Related Papers

Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology

|Journal of the National Comprehensive Cancer Network|2017|655

Intensive chemotherapy with cyclophosphamide, doxorubicin, high‐dose methotrexate/ifosfamide, etoposide, and high‐dose cytarabine (CODOX‐M/IVAC) for human immunodeficiency virus–associated Burkitt lymphoma

|Cancer|2003|151

HLA-Haploidentical Donor Lymphocyte Infusions for Patients with Relapsed Hematologic Malignancies after Related HLA-Haploidentical Bone Marrow Transplantation

|Biology of Blood and Marrow Transplantation|2013|113

Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes

|Journal of Clinical Oncology|2024|39

What Lies Within: Novel Strategies in Immunotherapy for Non-Small Cell Lung Cancer

|The Oncologist|2013|36